APRIL and BAFF: novel biomarkers for central nervous system lymphoma.
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
15 10 2019
15 10 2019
Historique:
received:
11
07
2019
accepted:
25
09
2019
entrez:
17
10
2019
pubmed:
17
10
2019
medline:
24
6
2020
Statut:
epublish
Résumé
Early diagnosis of CNS lymphoma (CNSL) is essential for successful therapy of this rapidly progressing brain tumor. However, in patients presenting with focal brain lesions, fast and reliable diagnosis of PCNSL remains a challenge. A proliferation-inducing ligand (APRIL) and B cell activating factor (BAFF) are important factors in the pathophysiology, diagnosis, and prognosis of systemic B cell malignancies. However, their utility as biomarkers for the diagnosis of CNSL and their effects on CNSL cells remain unclear. In this prospective study, we analyzed the levels of APRIL and BAFF in the cerebrospinal fluid (CSF) of 116 patients with suspected focal brain lesions, including 53 CNSL patients. Additionally, we serially measured their levels during chemotherapy and relapse. Furthermore, we analyzed the effect of APRIL and BAFF on two B cell lymphoma cell lines using proliferation, viability, and chemotaxis assays. CSF levels of APRIL and BAFF reliably differentiated CNSL from other focal brain lesions (including primary and metastatic brain tumors, autoimmune-inflammatory lesions, and neuroinfectious lesions) with a specificity of 93.7% (APRIL, BAFF) and a sensitivity of 62.3% (APRIL) and 47.1% (BAFF). Serial CSF analysis of CNSL patients during chemotherapy and relapse demonstrates a close correlation of APRIL CSF levels and the course of this disease. In vitro, APRIL and BAFF showed anti-apoptotic effects during MTX treatment and mediated chemotaxis of malignant B cells. This study extends the spectrum of valuable diagnostic biomarkers in CNSL. In patients with focal brain lesions, measurement of APRIL in CSF could help accelerating the diagnosis of CNSL. Moreover, our results highlight an important role of APRIL and BAFF in the pathophysiology of CNSL.
Sections du résumé
BACKGROUND
Early diagnosis of CNS lymphoma (CNSL) is essential for successful therapy of this rapidly progressing brain tumor. However, in patients presenting with focal brain lesions, fast and reliable diagnosis of PCNSL remains a challenge. A proliferation-inducing ligand (APRIL) and B cell activating factor (BAFF) are important factors in the pathophysiology, diagnosis, and prognosis of systemic B cell malignancies. However, their utility as biomarkers for the diagnosis of CNSL and their effects on CNSL cells remain unclear.
METHODS
In this prospective study, we analyzed the levels of APRIL and BAFF in the cerebrospinal fluid (CSF) of 116 patients with suspected focal brain lesions, including 53 CNSL patients. Additionally, we serially measured their levels during chemotherapy and relapse. Furthermore, we analyzed the effect of APRIL and BAFF on two B cell lymphoma cell lines using proliferation, viability, and chemotaxis assays.
RESULTS
CSF levels of APRIL and BAFF reliably differentiated CNSL from other focal brain lesions (including primary and metastatic brain tumors, autoimmune-inflammatory lesions, and neuroinfectious lesions) with a specificity of 93.7% (APRIL, BAFF) and a sensitivity of 62.3% (APRIL) and 47.1% (BAFF). Serial CSF analysis of CNSL patients during chemotherapy and relapse demonstrates a close correlation of APRIL CSF levels and the course of this disease. In vitro, APRIL and BAFF showed anti-apoptotic effects during MTX treatment and mediated chemotaxis of malignant B cells.
CONCLUSION
This study extends the spectrum of valuable diagnostic biomarkers in CNSL. In patients with focal brain lesions, measurement of APRIL in CSF could help accelerating the diagnosis of CNSL. Moreover, our results highlight an important role of APRIL and BAFF in the pathophysiology of CNSL.
Identifiants
pubmed: 31615554
doi: 10.1186/s13045-019-0796-4
pii: 10.1186/s13045-019-0796-4
pmc: PMC6792247
doi:
Substances chimiques
B-Cell Activating Factor
0
Biomarkers, Tumor
0
TNFSF13 protein, human
0
Tumor Necrosis Factor Ligand Superfamily Member 13
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102Références
Immunol Rev. 2011 Nov;244(1):115-33
pubmed: 22017435
J Neurooncol. 2011 Jan;101(1):33-9
pubmed: 20499137
Acta Neuropathol Commun. 2019 Mar 18;7(1):43
pubmed: 30885253
Leukemia. 2011 Dec;25(12):1797-807
pubmed: 21818113
PLoS One. 2013 Jul 29;8(7):e70924
pubmed: 23923031
Eur J Haematol. 2008 Sep;81(3):177-84
pubmed: 18510703
Ann Rheum Dis. 2007 May;66(5):700-3
pubmed: 17040963
J Neurol Sci. 2015 May 15;352(1-2):79-83
pubmed: 25847017
Int J Clin Exp Pathol. 2013 Sep 15;6(10):2048-55
pubmed: 24133582
Leukemia. 2009 Jan;23(1):170-7
pubmed: 18843286
Mod Pathol. 2009 Apr;22(4):547-55
pubmed: 19287466
Blood. 2002 Oct 15;100(8):2973-9
pubmed: 12351410
BMC Cancer. 2009 Mar 16;9:83
pubmed: 19291294
Blood. 1996 Mar 1;87(5):1985-9
pubmed: 8634448
Neuro Oncol. 2012 Mar;14(3):368-80
pubmed: 22156547
Br J Haematol. 2018 Aug;182(3):384-403
pubmed: 29808930
J Neuroimmunol. 2010 Mar 30;220(1-2):104-7
pubmed: 20149932
J Neurooncol. 2012 Sep;109(2):239-44
pubmed: 22729947
Blood. 2007 Jan 1;109(1):331-8
pubmed: 17190854
J Neurooncol. 2016 Aug;129(1):165-71
pubmed: 27294357
Neurology. 2008 Sep 30;71(14):1102-8
pubmed: 18824675
J Exp Med. 2000 Oct 2;192(7):953-64
pubmed: 11015437
Cancer Sci. 2018 Jan;109(1):225-230
pubmed: 29151258
Autoimmun Rev. 2010 Feb;9(4):224-8
pubmed: 19671451
J Immunol. 2004 Mar 1;172(5):3268-79
pubmed: 14978135
J Exp Med. 2005 Jan 17;201(2):195-200
pubmed: 15642740
Med Oncol. 2015 Jan;32(1):351
pubmed: 25428379
Neurol Int. 2013 Mar 21;5(1):e4
pubmed: 23717783
Eur J Cancer. 2015 Feb;51(3):382-90
pubmed: 25534293
Sci Rep. 2016 Dec 07;6:38671
pubmed: 27924864
Oncotarget. 2017 Jul 18;8(29):48157-48168
pubmed: 28636991
Blood. 2004 Oct 15;104(8):2247-53
pubmed: 15251985
Neuro Oncol. 2011 Oct;13(10):1090-8
pubmed: 21803762
Blood. 2009 May 7;113(19):4627-36
pubmed: 19258594
Ann Clin Transl Neurol. 2018 Oct 19;5(12):1611-1616
pubmed: 30564626
Nat Rev Rheumatol. 2014 Jun;10(6):365-73
pubmed: 24614588
Mult Scler. 2011 Jul;17(7):819-29
pubmed: 21372118
Neurol Sci. 2014 Feb;35(2):233-8
pubmed: 23832112
Cell Prolif. 2016 Apr;49(2):147-53
pubmed: 26990358
Nat Rev Neurol. 2012 Nov 5;8(11):613-23
pubmed: 23045237
Blood. 2013 Mar 28;121(13):2522-8
pubmed: 23355535
Oncotarget. 2017 Jan 31;8(5):7989-7998
pubmed: 28002793
Blood. 2013 Jun 6;121(23):4740-8
pubmed: 23570798
Blood. 2004 Jan 15;103(2):679-88
pubmed: 14504101
Nat Commun. 2015 Jun 11;6:7333
pubmed: 26065893
PLoS One. 2013 Dec 20;8(12):e83250
pubmed: 24376672
Acta Neurochir (Wien). 2008 Jan;150(1):23-9
pubmed: 18172567
Annu Rev Immunol. 2003;21:231-64
pubmed: 12427767
Ann Neurol. 2008 May;63(5):662-7
pubmed: 18481293
Curr Opin Immunol. 2007 Jun;19(3):327-36
pubmed: 17433868
J Neurooncol. 2015 Jan;121(1):177-83
pubmed: 25258254
J Immunol. 2015 Jan 15;194(2):542-52
pubmed: 25505277
Blood. 2008 Mar 1;111(5):2744-54
pubmed: 18172003
Semin Immunol. 2006 Oct;18(5):305-17
pubmed: 16916610
Neuro Oncol. 2016 Mar;18(3):361-7
pubmed: 26250566
J Clin Oncol. 1999 Feb;17(2):554-60
pubmed: 10080599
Ann Hematol. 2011 Dec;90(12):1391-8
pubmed: 21479535
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Oncogene. 2004 Apr 15;23(17):3005-12
pubmed: 14691452
Crit Rev Oncol Hematol. 2018 Jul;127:56-65
pubmed: 29891112
Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):311-24
pubmed: 12787568
Neuro Oncol. 2015 Nov;17(11):1497-503
pubmed: 26014047
J Exp Med. 2000 Jul 3;192(1):137-43
pubmed: 10880535
Hematol Oncol. 2014 Jun;32(2):57-67
pubmed: 23949943
Am J Hematol. 2009 Feb;84(2):71-3
pubmed: 19051265
Blood. 2011 Mar 17;117(11):3140-6
pubmed: 21200023
Neuro Oncol. 2017 Nov 29;19(12):1618-1627
pubmed: 28521029
Ann Biol Clin (Paris). 2005 Nov-Dec;63(6):631-7
pubmed: 16330382
J Clin Immunol. 2012 Oct;32(5):1007-11
pubmed: 22644841